| Outcome Measures: |
Primary: Change in Plasma LDL Cholesterol, Before and after 5 weeks of dapagliflozin on rosuvastatin background., 5 weeks | Secondary: Change in Plasma HDL Cholesterol, Change in plasma HDL cholesterol following dapagliflozin, 12 weeks|Change in Total Cholesterol, Change in total cholesterol following dapagliflozin, 5 weeks|Change in Plasma Triglycerides, Change in plasma Triglycerides following dapagliflozin, 5 weeks|Change in Plasma FFA, Change in plasma FFA following dapagliflozin, 5 weeks|Change in Cholesterol Fluxes, Including cholesterol production, cholesterol excretion, cholesterol degradation. Before and after 5 weeks of dapagliflozin on rosuvastatin background., 5 weeks|Change in Triglyceride Fluxes, Including cholesterol production, cholesterol excretion, cholesterol degradation. Before and after 5 weeks of dapagliflozin on rosuvastatin background, 5 weeks|Change in Peripheral Insulin Sensitivity, Before and after 5 weeks of dapagliflozin on rosuvastatin background, measured as glucose disposal during hyperinsulinemic euglycemic clamp, 5 weeks|Liver Fat MRI Spectrum, Before and after 5 weeks of dapagliflozin on rosuvastatin background, 5 weeks|Fecal Microbiome Composition, Before and after 5 weeks of dapagliflozin on rosuvastatin background, different bacterial strains will be quantified in fresh fecal samples., 5 weeks|Bile Salt Excretion, Before and after 5 weeks of dapagliflozin on rosuvastatin background, 5 weeks|Urinary Glucose Excretion, Before and after 5 weeks of dapagliflozin on rosuvastatin background, 5 weeks|Urinary Sodium Excretion, Before and after 5 weeks of dapagliflozin on rosuvastatin background, 5 weeks
|
